Shares of Cipla Limited rose as much as 3.55% to ₹1,465.90 in early trade on Friday, following the company’s announcement that it has received final approval from the US Food and Drug Administration (USFDA) for its generic version of Bristol Myers Squibb’s Abraxane®. The approval pertains to Cipla’s Abbreviated New Drug Application (ANDA) for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial.
Abraxane® is a prominent chemotherapy drug used in the treatment of metastatic breast cancer, non-small cell lung cancer (NSCLC), and metastatic pancreatic cancer. Cipla’s AB-rated generic equivalent opens the doors for affordable access to this critical cancer therapy in the U.S., one of the most lucrative pharmaceutical markets globally.
Cipla has confirmed that it plans to commercially launch the product in the first half of FY26, marking a significant step forward in strengthening its U.S. oncology pipeline. The launch is expected to enhance Cipla’s revenues from the complex injectables segment and improve its visibility in the high-margin U.S. generic market.
The company’s market capitalization stood at ₹1.18 trillion as of Friday morning. The stock has traded in a tight range today between ₹1,460.00 and ₹1,460.00, with a 52-week range of ₹1,317.25 to ₹1,702.05.
With this regulatory milestone, Cipla is likely to remain in focus as investors gauge the earnings potential from this critical U.S. oncology launch.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
